secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cellectar Biosciences, Inc. (CLRB)
CIK:        0001279704
Form:       8-K
Filed at:   2024-11-01T23:59:59+00:00
Accession:  0001104659-24-113549
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cellectar regains Nasdaq compliance after filing restated financials and Form 10-Q
--------------------------------------------------------------------------------

- Received Nasdaq letter dated Oct 31, 2024 confirming compliance with Listing Rule 5250(c)(1).
- Filed on Oct 29, 2024 restated audited financials for FY2022 and FY2023 and restated quarterly periods in 2022-2023.
- Also filed restated Q1 2024 quarterly report (Form 10-Q/A) and regular Q2 2024 quarterly report (Form 10-Q).
- Nasdaq noted the matter is now closed, removing delisting risk from late filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1279704/000110465924113549/0001104659-24-113549-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1279704/000110465924113549/tm2427349d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-113549

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer